Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Quick ratio

Quick ratio at other companies

Avanos Medical logo
Avanos MedicalAVNS
1.4×-0.2×
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
1.7×+0.7×
AtriCure logo
AtriCureATRC
3.2×+0.3×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

quick assets/total current liabilities=3.4×

Based on the most recent quarter.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s quick ratio?
Pacira BioSciences, Inc. (PCRX) reported quick ratio of 3.4× in Q1 2026.
How has Pacira BioSciences, Inc.'s quick ratio changed year-over-year?
Pacira BioSciences, Inc.'s quick ratio increased by 68.4% year-over-year, from 2× to 3.4×.
What is the long-term trend for Pacira BioSciences, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s quick ratio has grown at a 7.2% compound annual growth rate (CAGR), from 2.3× to 3.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.